Drug intelligence / Profile preview

B-013

Development stage: Phase 3
Lead developer: Shanghai Cross-linked Pharmaceutical Research and Development
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

B-013 is a monoclonal antibody drug candidate that acts as an antagonist of the inactive tyrosine-protein kinase transmembrane receptor ROR1. It was initially developed by Shanghai Pharmaceuticals Holding. The primary mechanism of action is antagonism of ROR1, a receptor implicated in several cancers. B-013 has reached Phase 2/3 clinical development for various solid tumors, including triple negative breast cancer and multiple forms of platinum-resistant gynecologic cancers[1].

Targets

ROR1 (Receptor tyrosine kinase-like orphan receptor 1)

Beyond the preview

Go deeper on B-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-013.

Explore the full profile